% | $
Quotes you view appear here for quick access.

Incyte Corporation Message Board

  • jacosa jacosa Jan 15, 2014 7:57 PM Flag

    More JPM conference

    Getting long, and anyway I'm about to open the Jar of Winds.

    Listened to the Geron presentation. "Chip" Scarlett seems to have been leaning on Tefferi for more information, to some effect. Patients remain responsive to IM for the duration of the study (nobody has yet gone from response to no response). The treatment regimen being evaluated now for maintenance (an infusion every six weeks) sounds like it would probably be tolerable to patients. Geron is now planning a real phase 2. There was something about "these slides were prepared for a different purpose" that I take as a broad hint that Geron is being shopped around. Even with a deep-pocketed buyer, I don't see marketing of IM in less than 5 years.

    Over-interpreting the figure concerning length of survival for different MF risk categories, median time to progression for the lowest risk category looks like 7 years. I've said that if Incyte wants to generate survival data that can unambiguously go on the label, they'll need to do a study on patients for whom waiting to treat is considered a good option--exactly these lowest risk patients. A 10-year study on patients who don't feel sick (or at risk) may not be workable. Can a REAL hem/onc help us out here? Is there an identifiable group of people minimally ill with MF who "Look about to progress?"

    SortNewest  |  Oldest  |  Most Replied Expand all replies
69.72-1.28(-1.80%)12:55 PMEST